FORADIL Drug Patent Profile

Which patents cover Foradil, and when can generic versions of Foradil launch?

Foradil is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in FORADIL is formoterol fumarate. There are nineteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the formoterol fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Foradil

A generic version of FORADIL was approved as formoterol fumarate by TEVA PHARMS USA INC on June 22^nd, 2021.

Summary for FORADIL

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	34
Patent Applications:	210
What excipients (inactive ingredients) are in FORADIL?	FORADIL excipients list
DailyMed Link:	FORADIL at DailyMed

Recent Clinical Trials for FORADIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	PHASE4
Fundacio Privada Mon Clinic Barcelona	PHASE4
University of Florida	Phase 1

See all FORADIL clinical trials

US Patents and Regulatory Information for FORADIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	FORADIL	formoterol fumarate	POWDER;INHALATION	020831-001	Feb 16, 2001		DISCN	Yes	No
Novartis	FORADIL CERTIHALER	formoterol fumarate	POWDER;INHALATION	021592-001	Dec 15, 2006		DISCN	No	No

Expired US Patents for FORADIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	FORADIL	formoterol fumarate	POWDER;INHALATION	020831-001	Feb 16, 2001	6,488,027
Novartis	FORADIL	formoterol fumarate	POWDER;INHALATION	020831-001	Feb 16, 2001	6,887,459

International Patents for FORADIL

See the table below for patents covering FORADIL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	283083
Australia	3032399
Australia	750844

Supplementary Protection Certificates for FORADIL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
0613371	2002C/022	Belgium		PRODUCT NAME: BUDESONID. MICRONIS. AND FORMOTEROL. FUMARAS DIHYDR., NATL REGISTRATION NO/DATE: 624 IS 234 F 0 20010129; FIRST REGISTRATION: SE 16047 20000825
2435025	300995	Netherlands		PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220

Market Dynamics and Financial Trajectory for FORADIL (formoterol)

Last updated: April 24, 2026

FORADIL is a long-acting bronchodilator brand built on formoterol for asthma and chronic obstructive pulmonary disease (COPD). Its market trajectory is shaped by patent and exclusivity expiry, the shift toward inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) combinations, and aggressive price competition from authorized generics and therapeutically substitutable regimens. Revenue performance has generally moved from branded growth to a declining mature asset profile, with later-stage pricing pressure and volume shifts driven by guideline adherence and formulary placement.

What is FORADIL and where does it sit in respiratory prescribing?

FORADIL is an inhaled LABA using formoterol as the active ingredient. Inhaled LABAs are used to improve airflow by relaxing bronchial smooth muscle. Clinically, the market dynamics for FORADIL depend on whether prescribers deploy LABA monotherapy versus combination therapy (typically an ICS/LABA fixed-dose inhaler) and on whether payers steer patients to preferred products via formulary tiers, prior authorization, and step therapy.

Therapeutic role

• Primary mechanism: long-acting beta-2 agonism via formoterol
• Use cases: asthma (in combination contexts in many jurisdictions) and COPD maintenance bronchodilation
• Clinical positioning risk: LABA monotherapy has faced tighter treatment constraints in asthma due to safety and guideline emphasis on ICS-containing regimens

Market substitution map

FORADIL faces two layers of substitution:

1. Within-class substitution: other LABAs (shorter onset, different devices, different dosing schedules)
2. Regimen substitution: ICS/LABA fixed-dose products and other guideline-preferred maintenance approaches that reduce reliance on LABA monotherapy

What market forces drive FORADIL pricing and share loss?

The branded-to-generic transition is the dominant financial driver for mature respiratory brands. For FORADIL, the market after exclusivity has typically aligned with:

• Authorized generic entry and subsequent non-authorized generic competition
• Device and convenience competition shifting demand across inhalers
• Formulary consolidation favoring fewer preferred inhalers per payer network

Key pricing and access levers

Lever	How it changes FORADIL economics	Expected directional impact
Generic entry and interchangeability	Lowers net price through payer switching and pharmacy substitution	Revenue decline via price compression
Formulary tier placement	Creates discontinuation pressure at retail and institutional formularies	Volume loss risk
Step therapy and prior authorization	Delays initiation or forces trial of preferred products	Slower uptake and churn
Regimen preference for ICS/LABA	Reduces TAM for LABA-only maintenance in asthma	Structural demand shrink

What does the financial trajectory typically look like for FORADIL?

FORADIL’s financial trajectory is characteristic of a respiratory branded asset after exclusivity:

• Early-to-mid lifecycle: brand adoption with market learning and clinician familiarity
• Late lifecycle: steady erosion as generics and therapeutically substitutable products displace branded share
• Post-exclusivity: net revenue tracking predominantly to residual volume, competitive pricing, and contracting outcomes

Revenue shape (qualitative)

• Branded peak period: highest net sales occurs before generic entry and before combination therapy becomes the dominant formulary pathway
• Transition years: sales decline accelerates during generic rollout windows and payer renegotiation cycles
• Mature years: sales stabilize at a reduced base if the product retains device/device-usage loyalty or niche prescribing

This trajectory has been common for inhaled mono-therapy LABA brands as fixed-dose combination therapy gained guideline centrality.

Where do patents and regulatory exclusivities impact the timeline?

Financial turning points for FORADIL are tied to:

• expiration of compound and formulation protections (jurisdiction-specific),
• regulatory exclusivities (where applicable),
• and generic entry approvals for formoterol products with comparable dosing and device characteristics.

For FORADIL and formoterol-containing products, patent and exclusivity landscapes are primarily evaluated at the US Orange Book and corresponding international registers, with device- and formulation-specific patents often extending periods for certain inhalers but not for the active ingredient once core protections expire.

Regulatory anchors

The FDA’s product labeling and approval records establish the drug’s identity and intended use in asthma and COPD.

• FORADIL (formoterol fumarate) is a bronchodilator approved for asthma and COPD maintenance. (FDA label information reflects the product’s role and boxed safety context.) [1]

How do inhaler device and substitution patterns affect volume?

Inhaler therapy is device-dependent. Even when active ingredients are equivalent, device usability affects adherence and payer preference.

Device-driven dynamics

• If a competitor’s inhaler has better patient acceptance or fewer steps in administration, it gains share even if the drug is class-equivalent.
• Contracting outcomes often anchor around a limited number of inhalers with favorable rebates and reimbursement.
• For multi-dose inhalers, pharmacy-level substitution can shift demand quickly after generic approval.

Substitution with ICS/LABA

In asthma management, guideline emphasis on controller therapy changes the competitive set. Where fixed-dose ICS/LABA is preferred, LABA-only maintenance loses patient slots over time.

What payer and guideline shifts most pressure FORADIL?

Respiratory care has moved toward:

• controller-first frameworks for asthma,
• maintenance regimens that combine anti-inflammatory therapy and bronchodilation,
• standardized step therapy that favors preferred formulary combinations.

This shift is particularly impactful for LABA monotherapy brands because it narrows the eligible patient populations that remain on LABA without ICS.

Practical outcome for market economics

• Higher churn: patients switching to ICS/LABA
• Lower incremental uptake: fewer new patients started on LABA alone
• Constrained re-entry: when step-down or switching occurs, it often cycles among combination products rather than back to mono-therapy

What is the competitive set against FORADIL today?

FORADIL faces competition from:

• other LABAs (same or near-same onset profiles),
• combination ICS/LABA inhalers that displace LABA monotherapy, and
• generic formoterol and other inhaled bronchodilator products offering lower net prices.

The competitive set is intensified by pharmacy substitution and payer formulary compression. Inhaled therapies are among the most competitively priced drug classes once generics enter.

How does cashflow typically behave post-branded decline in inhaled respiratory assets?

For mature inhaled products like FORADIL, financial performance tends to be defined by:

• declining gross-to-net as rebates and contracting intensify to defend shelf share,
• reduced promotional intensity as share erodes,
• reliance on residual loyalty and institutional use patterns,
• and margin compression from price controls and competition.

The result is a lower-growth revenue base with constrained operating leverage.

What business implications follow for R&D and investment decisions?

FORADIL is not a platform candidate in the classic sense; its pathway is a test case for how respiratory market structure punishes monotherapy positioning once guidelines and formularies favor combinations. Commercial upside for next-generation formoterol-based or LABA-based products depends on:

• differentiated device performance or improved adherence,
• combination or regimen advantage (ICS/LABA or triple therapy),
• payer contracting strategy aligned to step therapy,
• and a protection stack that covers not just active ingredient but also device and formulation until meaningful market windows close.

Key Takeaways

• FORADIL’s market dynamics are governed by generic substitution, formulary tiering, and the shift from LABA monotherapy to controller-based combinations (especially in asthma).
• Financial trajectory typically follows a mature-brand pattern: branded peak, accelerated decline during generic entry and contracting renegotiations, then a reduced revenue base sustained by residual volume and device loyalty.
• Inhaler device usability and payer contracting can materially affect volume even when active ingredients are equivalent.
• Any future commercial model for formoterol/LABA assets must address regimen placement (ICS/LABA or beyond), not just bronchodilator efficacy.

FAQs

1. Is FORADIL still a meaningful product in inhaled LABA markets?
   Its branded profile is constrained by generic competition and formulary preference for combination regimens, which reduces addressable share versus earlier lifecycle years.

2. What most determines FORADIL net sales after exclusivity?
   Net price compression from generics and contracting, plus volume loss from payer switching and regimen displacement toward ICS/LABA.

3. Do device differences drive demand for FORADIL versus competitors?
   Yes. Inhaler administration steps, patient handling characteristics, and payer preferred-device lists affect adherence and switching.

4. How do guideline trends in asthma influence FORADIL demand?
   Guideline emphasis on controller therapy (typically ICS-based) reduces the pool of patients maintained on LABA-only therapy.

5. What protection strategy matters most for formoterol/LABA commercial success?
   Protection must extend beyond the active ingredient into device and formulation where possible, and the product must win a formulary and regimen pathway, not only efficacy.

---

References

[1] U.S. Food and Drug Administration. (n.d.). FORADIL (formoterol fumarate) prescribing information / label information. FDA. https://www.accessdata.fda.gov/